原发性骨质疏松症患者骨组织肿瘤坏死因子和白细胞介素6的？…

目的 探讨肿瘤坏死因子和白细胞介素６对原发性骨质疏松症患者骨组织的影响。方法 手术时取出４０例患者股骨颈部松质骨，进行组织培养，检测肿瘤坏死因子和白细胞介素６的活性。结果 原发性骨质疏松症患者骨组织中肿瘤坏死因子和白细胞介素６的活性显著增强（Ｐ〈０．０１）。结论 肿瘤坏死因子和白细胞介素６参与了骨质疏松症的病理过程。     

白细胞介素6在老年男性原发性骨质疏松症发病中的作用

为探讨白细胞介素６（ＩＬ－６）在老年男性原发性骨质疏松症发病中的作用，我们采用国际上通用的ＩＬ－６依赖性细胞株ＭＨ６０．ＢＳＦ增殖反应ＭＴＴ法检测了老年前期和老年期男性外周血单个核细胞培养上清ＩＬ－６水平以及血清性激素（雌二醇、睾酮），甲状旁腺激素（ＰＴＨ）、骨钙素（ＢＧＰ）以及尿钙（Ｃａ）与肌酐（Ｃｒ）比值等水平的变化，单光子骨密度仪测定受试者非优势臂桡、尺骨中远端１／３交界处桡、尺骨骨密度（ＢＭＤ）。结果，疏松组ＩＬ－６水平高于非疏松组；多元回归分析发现ＩＬ－６与ＢＭＤ３（桡、尺骨骨密度均值）、Ｔ和Ｅ２呈有意义的负相关，与尿Ｃａ／Ｃｒ比值呈正相关；ＢＭＤ３还与身高、体重、雌二醇和睾酮呈有意义正相关；结果提示，随增龄引起性激素水平的减退和其它因素的影响，导致分泌ＩＬ－６细胞活化，ＩＬ－６分泌增多，从而刺激骨吸收，骨吸收超过骨形成就会导致骨质疏松的发生。     

白细胞介素—6在老年女性原发性骨质疏松症发病中的作用

为探讨白细胞介素－６（ＩＬ－６）在老年女性原发性骨质疏松症（ＯＰ）发病中的作用，本文采用ＩＬ－６依赖性细胞株ＭＨ６０．ＢＳＦ增殖反应ＭＴＴ法检测了３０例老年女性骨质疏松性骨折患者和２４例正常者以及１４例健康绝经前女性外周血单核细胞培养上清（ＰＢＭＣ）ＩＬ－６水平以及血清雌激素（Ｅ２）、骨钙素（ＢＧＰ）等水平的变化。结果：绝经后妇女ＩＬ－６水平高于绝经前，而ＯＰ组又高于ＮＯＰ组。以ＯＰ组ＩＬ－６为因     

一氧化氮在原发性骨质疏松症中的作用探讨

目的　探讨一氧化氮在原发性骨质疏松症中的作用。方法　酶法测定 １６ 例老年骨质疏松症患者及２１ 例青壮年创伤患者血清内一氧化氮（ＮＯ）水平,并检测血清内骨钙素（ＢＧＰ）及白细胞介素－６（ＩＬ－６）水平的变化。结果　老年骨质疏松症组ＮＯ、ＩＬ－６ 水平明显高于青壮年组（Ｐ＜ ０．０５）,ＢＧＰ显著高于青壮年组（Ｐ＜ ０．０１）。青壮年组ＮＯ 与ＩＬ－６、ＢＧＰ呈正相关,但无显著性意义（ｒ＝０．０４３,ｒ＝ ０．０２８,Ｐ＞ ０．０５）;而老年骨质疏松症患者体内ＮＯ 与ＩＬ－６ 的变化呈负相关（ｒ＝ － ０．５７９,Ｐ＜ ０．０５）,与ＢＧＰ正相关（ｒ＝ ０．５４９,Ｐ＜ ０．０５）,血清内ＩＬ－６ 的水平与骨质疏松的程度密切相关。结论　老年骨质疏松症患者由于体内ＮＯ的内源性合成相对减少,对促进破骨细胞活性的细胞因子抑制作用减弱,使骨吸收加速,从而导致骨质疏松的发生,因而促进内源性ＮＯ 的合成有助于骨质疏松症的防治。     

瘢痕疙瘩和正常皮肤成纤维细胞对白介素—1β和白介素—6的…

OBJECTIVE: The purpose of this study was to explore the responses of fibroblasts from keloids and normal skin to interleukin-1 beta and interleukin-6. METHODS: Six samples of keloids and 6 samples of normal skin were collected as the experimental and control group respectively. The means of cell culture was used to investigate the responses of fibroblasts from three different parts of keloids and normal skin to interleukin-1 beta (200 U/ml) and interleukin-6 (100 U/ml). RESULTS: Interleukin-1 beta could inhibit the growth of fibroblasts from the proliferative part of keloids but stimulate growth of those from normal skin, while it did not affect the growth of those from other parts of keloids. Fibroblasts from different parts of keloids and normal skin were all inhibited by interleukin-6. CONCLUSION: The responses of fibroblasts from three parts of keloids and normal skin to interleukin-1 beta and interleukin-6 were not much similar.     

IL——1对病理性瘢痕成纤维细胞超微结构的影响

目的：阐明白细胞介素－１对病理性瘢痕效应的作用机理。方法：观察白细胞介素－１对病理性瘢痕成纤维细胞超微结构的影响。结果：该介素明显破坏了线粒体、粗面内质网、核糖体等重要细胞器。结论：证明白细胞介素－１是成纤维细胞合成胶原的负性调节因子。     

IL—6及其在烧伤中的意义

ＩＬ－６是一种多功能的细胞因子，具有诱导Ｂ细胞分化，刺激浆细胞瘤和杂交瘤细胞生长，诱导急性期蛋白质合成，参与血细胞生长，抗病毒等效应，ＩＬ－６为急性期反应的重要细胞因子，在烧伤早期和脓毒症时期升高，前者与损伤后急笥期反应有关，后者与感染有关，并对预测烧伤预后有一定意义。     

膀胱肿瘤患者尿液IL—6活性检测的临床意义

为了探讨白细胞介素６（ＩＬ６）活性与膀胱肿瘤的关系，采用ＥＬＩＳＡ法对３７例膀胱肿瘤患者手术前后尿液ＩＬ６活性进行了免疫学检测，发现膀胱肿瘤患者尿液ＩＬ６活性较正常对照组显著升高（Ｐ＜０．０１），并与膀胱肿瘤临床分期有明显相关性，而与肿瘤的分级无关；肿瘤切除后尿液ＩＬ６活性明显降低（Ｐ＜０．０１）。结果提示ＩＬ６活性与膀胱肿瘤分期有关，并可作为判断膀胱肿瘤生物学行为的一项有用指标。     

大鼠骨质疏松模型血清中一氧化氮和IL—6水平及意义

目的：测定骨质疏松模型大鼠血清中一氧化氮（NO）和IL－6水平，探讨其意义。方法：8月龄成年雌性SD大鼠随机分假手术对照组和去卵巢骨质 疏松模型组，术后第12周测量全身骨密度后处死，取血清用硝酸还原酶法测定NO水平，放免法测定IL－6和雌激素水平，结果：去卵巢骨质疏松模型组大鼠与假手术对照组相比，骨密度下降，胫骨骨小梁宽度变窄，间距变宽，小梁占视野面积比降低，血清中雌激素和NO含量显著下降，IL－6含量明显升高，大鼠骨密度与血清中雌激素和NO含量正相关，与IL－6含量负相关，结论：大鼠骨质疏松模型血清中NO水平降低，IL－6水平升高，NO和IL－6在骨质疏松的发生发展中起重要作用。     

老年性骨质疏松症患者腰椎骨基质改变

目的 :研究骨质疏松症患者骨基质的改变及其影响因素。方法 :采用老年性骨质疏松症患者和骨密度正常者腰椎椎板近关节突部松质骨标本 ,行扫描电镜观察 ,同时以IL 6单克隆抗体进行免疫组化研究。结果 :与对照组相比 ,骨质疏松症患者骨组织扫描电镜显示小梁数量减少、变细 ,小梁间距离增宽 ,小梁表面粗糙 ,胶原纤维肿胀、排列杂乱 ;免疫组化示骨组织中成骨细胞、骨髓基质细胞IL 6染色阳性数明显多于对照组 (P <0 .0 5)。结论 :除骨矿因素外 ,骨质疏松症患者骨基质中胶原纤维肿胀、排列杂乱亦可能会导致骨力学强度下降 ,这也许与局部IL 6的水平表达较高 ,促进Ⅰ型原胶原酶mRNA的表达有关     

辛伐他汀对结直肠癌患者IL-6与IL-8血清表达及癌细胞分泌影响的研究

目的:研究辛伐他汀对结直肠癌患者IL-6及IL-8血清表达和癌细胞分泌的影响,初步探讨辛伐他汀在结直肠癌中的治疗机制。方法:应用ELISA检测结直肠癌患者与健康对照者血清中IL-6及IL-8水平,应用RT-PCR比较IL-6与IL-8在结直肠癌及癌旁组织的表达情况;应用ELISA检测结直肠癌患者辛伐他汀治疗后血清IL-6与IL-8的变化规律。应用ELISA检测辛伐他汀干预后结直肠癌细胞株(HT-29与Ca-co-2)上清中IL-6与IL-8变化。结果:结直肠癌患者血清IL-6与IL-8水平显著高于健康对照者(P<0.05)。IL-8 mRNA表达水平在癌组织明显高于癌旁组织(P<0.05);而IL-6 mRNA在癌组织与癌旁组织表达差异无统计学意义(P>0.05)。结肠癌患者应用辛伐他汀(80 mg/d)治疗14 d后,血清IL-6水平显著降低(P<0.05),而IL-8无明显变化(P>0.05)。应用浓度达到5μmol/L以上辛伐他汀干预结直肠癌细胞株HT-29与Caco-2后,其IL-6及IL-8分泌明显下降(P<0.05)。结论:辛伐他汀可以降低结直肠癌患者血清IL-6的水平,并可以抑制结直肠癌细胞IL-8与IL-6分泌。     

白介素6在动物多器官衰竭中的变化及其意义

在家兔多器官衰竭ＭＯＦ模型上动态观察了白介素６（ＩＬ－６）水平变化，并对ＩＬ－６在ＭＯＦ的发生和发展过程中的意义进行了探讨。结果显示，实验组动物于休克及注射内毒素后ＩＬ－６水平明显升高；ＭＯＦ动物ＩＬ－６水平明显高于ＮＭＯＦ动物；衰竭器官≥３的动物ＩＬ－６水平明显高于２个器官衰竭的动物；３６ｈ以内死亡的动物显著高于３６ｈ以后死亡的动物；ＩＬ－６水平与各主要器官功能变化，ＭＯＦ发生率，器官衰竭数目。     

IL-6 and IL-8 response to erythropoietin therapy in radical hysterectomy

BACKGROUND: The use of recombinant human erythropoietin (rHuEPO) improves autologous blood donation before elective surgery. However, there are other studies indicating that rHuEPO may suppress postoperative endogenous production of erythropoietin and stimulate inflammatory mediator release. Weekly donations generate only a moderate increase in endogenous erythropoietin production. We scheduled patients with cancer to predeposit three units of blood in 2 weeks, with or without rHuEPO therapy. The aim was to determine whether rHuEPO therapy and/or an aggressive donation schedule alter perioperative erythropoietin concentrations and whether rHuEPO therapy leads to the release of the pro-inflammatory cytokines IL-6 and IL-8. METHODS: Thirty women scheduled for radical hysterectomy and pelvic lymphadenectomy were randomly assigned to either a control group with no rHuEPO therapy or to receive rHuEPO. Three units of whole blood were collected from each patient before the operation. Concentrations of haemoglobin, erythropoietin (s-EPO) and cytokines (IL-6 and IL-8) were repeatedly analyzed before and after the operation. RESULTS: During the preoperative donation period, median s-EPO levels in the control group increased from 7 to 14 IU l(-1). There was a great increase in s-EPO concentrations 1 h postoperatively in the rHuEPO group compared with the control group (P < 0.001). IL-6 and IL-8 were not significantly changed after intravenous administration of rHuEPO. CONCLUSION: The use of rHuEPO therapy to optimise autologous blood donation does not influence IL-6 and IL-8 release. 1 h postoperatively rHuEPO therapy resulted in elevated s-EPO concentrations. There was, however, no difference in s-EPO between the groups from day 1 postoperatively and until the end of the study.     

祛风通络方对系膜增生性肾小球肾炎大鼠蛋白尿及血清IL-6与IL-8的影响

目的：探讨祛风通络方对系膜增生性肾小球肾炎大鼠蛋白尿及血清白细胞介素-6（IL-6）、白细胞介素-8（IL-8）的影响。方法：采用免疫法制备系膜增生性肾小球肾炎大鼠模型,应用磺柳酸法测定大鼠24h尿蛋白定量,双抗体夹心ELISA法检测大鼠血清IL-6、IL-8,光镜下观察各组大鼠肾小球系膜区（GMC）及细胞外基质（ECM）积聚变化。结果：模型组与正常对照组比较24h尿蛋白定量及血清IL-6、IL-8明显升高（P〈0.01）;祛风通络方组24h尿蛋白定量及血清IL-6、IL-8均明显低于模型组（P〈0.01）;肾组织形态学观察显示祛风通络方组个别区域肾小球系膜细胞轻度增生,系膜区轻度增宽,管腔无挤压现象,较模型组明显改善。结论：祛风通络方组降低系膜增生性肾小球肾炎大鼠尿蛋白,降低血清IL-6、IL-8水平,减轻系膜细胞增生和细胞外基质增加,延缓或减轻肾组织损伤,保护肾功能。     

颅脑损伤后血清TNF-α和IL-6的表达及对预后影响的临床研究

目的探讨颅脑损伤后血清TNF-α和IL-6的表达及对预后的影响。方法采用双抗体夹心ABC-ELISA方法,检测颅脑损伤后血清中TNF-α和IL-6的含量,比较颅脑损伤分级与血清中TNF-α和IL-6含量之间的关系以及外伤后的变化趋势,并探讨其对临床预后的影响。结果重型颅脑损伤后血清TNF-α和IL-6明显升高,在不同时间轻型、中型颅脑损伤组对比有明显差异(P<0.01)。结论血清中TNF-α和IL-6表达在重型颅脑损伤中明显增高,与颅脑损伤轻重成正比,并与预后密切相关。     

Effects of Alendronate on Bone Density in Men with Primary and Secondary Osteoporosis

Alendronate has been reported to increase bone mineral density (BMD) and reduce fracture risk in women with osteoporosis. As there are no proven safe and effective treatments available for men with osteoporosis, we compared the effects of alendronate (10 mg/day) on BMD, measured using dual-energy X-ray absorptiometry, in a 12-month prospective, controlled, open label study involving (i) men with primary (n= 23) or secondary osteoporosis (n= 18), (ii) postmenopausal women with primary (n= 18) or secondary (n= 21) osteoporosis, and (iii) 29 male and 14 female untreated controls matched by age, height and weight. The patients had one or more vertebral fractures and ranged in age from 34.6 to 85.1 years. BMD was detectably increased relative to baseline by 6 months, and increased by comparable amounts in males and females with primary or secondary osteoporosis. At 12 months, lumbar spine BMD was 5.4%± 1.1% to 7.0%± 2.2% higher in the treated groups compared with baseline and controls (p<0.05 to 0.0001). Trochanteric BMD increased by 2.6%± 1.5% and 3.7%± 1.7% in treated men with primary and secondary osteoporosis, respectively (p = 0.06 to 0.08), and by 3.9%± 1.3% in treated women with primary osteoporosis (p<0.01) after 12 months. No significant changes were detected at the femoral neck or Ward’s triangle. BMD remained unchanged in controls. We infer that alendronate has comparable incremental effects on BMD in men and women with primary and secondary osteoporosis within 12 months of treatment. The changes are in the order of 0.5 SD – effects associated with a clinically worthwhile reduction in fracture risk. The data provide room for optimism regarding the role of alendronate in the treatment of osteoporosis in men. Randomized, double-masked and placebo-controlled trials are needed to confirm these preliminary findings and demonstrate antifracture efficacy using vertebral and nonvertebral fracture rates as the primary endpoint. Received: 23 February 1999 / Accepted: 2 June 1999     

Bone Mineral Density and Bone Size in Men With Primary Osteoporosis and Vertebral Fractures

The bone mineral density (BMD) at the lumbar spine, proximal femur, and total skeleton was evaluated in 38 men with primary osteoporosis and vertebral fractures. BMD of the patients was significantly reduced over all skeletal areas compared with controls. The Z-score of the lumbar spine (−2.8 ± 0.9) was less than that of the other areas (P < 0.001) except the legs (−2.5 ± 1.1) (p.n.s.) showing that bone loss had a tendency to be greater over the axial skeleton. Vertebral dimensions compared with age-matched controls were as follows: projected L2–L4 area (cm 2): 45.7 ± 5.6 versus 53.7 ± 3.6 (P < 0.001); vertebral width (cm): 4.37 ± 0.44 versus 4.90 ± 0.36 (P < 0.001). Serum biochemical parameters and testosterone levels were similar between osteoporotic and control men. We conclude that men with vertebral osteoporotic fractures have reduced vertebral BMD and vertebral dimensions compared with age-matched controls. Thus, these findings indicate that the achievement of a reduced bone size at the end of the growth period or a failure of periosteal increase during adult life is likely to contribute to the pathogenesis of the vertebral fractures observed in older men. Received: 31 January 1997 / Accepted: 2 July 1997